(Q33368192)

26 July 2017

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation (English)

1 reference

26 July 2017

1 reference

2

Elke Schaeffeler

0 references

Meinrad Gawaz

9

object named as

Meinrad Gawaz

1 reference

26 July 2017

1

Tobias Geisler

1 reference

26 July 2017

Juergen Dippon

3

1 reference

26 July 2017

Stefan Winter

4

1 reference

26 July 2017

Verena Buse

5

1 reference

26 July 2017

Christian Bischofs

6

1 reference

26 July 2017

Christine Zuern

7

1 reference

26 July 2017

Klaus Moerike

8

1 reference

26 July 2017

Matthias Schwab

10

1 reference

26 July 2017

1 September 2008

1 reference

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

1251-1259

1 reference

26 July 2017

9

1 reference

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

26 July 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Platelet activation after stenting with heparin-coated versus noncoated stents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Frequency of C3435T polymorphism of MDR1 gene in African people

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Identification of the platelet ADP receptor targeted by antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

CYP2C19 polymorphism and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Clinical implications of CYP3A polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Pharmacogenomics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1251

10.2217/14622416.9.9.1251

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference